Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.525
+0.025 (1.00%)
At close: Nov 4, 2024, 4:00 PM
2.650
+0.125 (4.95%)
After-hours: Nov 4, 2024, 6:19 PM EST

Company Description

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.

Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.

The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration.

The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011.

Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Inc.
Galectin Therapeutics logo
Country United States
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Joel Lewis

Contact Details

Address:
4960 Peachtree Industrial Boulevard, Suite 240
Norcross, Georgia 30071
United States
Phone (678) 620-3186
Website galectintherapeutics.com

Stock Details

Ticker Symbol GALT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001133416
CUSIP Number 363225202
ISIN Number US3632252025
Employer ID 04-3562325
SIC Code 2834

Key Executives

Name Position
Joel Lewis President, Chief Executive Officer and Director
Jack W. Callicutt CPA Chief Financial Officer, Treasurer and Corporate Secretary
Robert Tritt General Counsel
Jeff Katstra Head of CMC and Pharmaceutical Development
Khurram Jamil M.D. Chief Medical Officer
Beth Knowles Executive Assistant and Officer Manager

Latest SEC Filings

Date Type Title
Oct 4, 2024 144 Filing
Sep 9, 2024 8-K Current Report
Aug 13, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
Aug 1, 2024 8-K Current Report
May 15, 2024 8-K Current Report
May 15, 2024 10-Q Quarterly Report
Mar 29, 2024 8-K Current Report
Mar 29, 2024 10-K Annual Report
Dec 11, 2023 8-K Current Report